Novavax Inc., of Gaithersburg, Md., said it plans to raise $100 million in a new public offering. Proceeds from the offering will be used for the advancement of its clinical-stage vaccine candidates, research, manufacturing and process development activities, capital expenditures and other strategic purposes.